Abstract:Introduction Patients with transthyretin cardiac amyloidosis (ATTR-CA) and heart failure do not tolerate beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors due to side effects and the efficacy of these agents remains uncertain in this patient population. Sodium-glucose transporter 2 inhibitors (SGLT2i) have significantly improved clinical outcomes in patients with heart failure (irrespective of ejection fraction) with few side effects. However, there remains a lack of data on the safety and tolerability of SGLT2i in patients with ATTR-CA. Hypothesis This observational study describes the tolerability and safety of SGLT2i in patients with ATTR-CA and heart failure. Methods A single-center retrospective observation of consecutive adult patients with ATTR-CA initiated on SGLT2i from January 2020-March 2023. Results Our study involved 53 patients with ATTR CA (74% Wild-Type); mean age 81 years (SD ± 8), 77% white, 72% men, 32% had diabetes mellitus (DM), and 51% with at least stage 3 chronic kidney disease with a mean glomerular filtration rate of 58 mL/min/1.73m (SD ±18). The median left ventricular ejection fraction (LVEF) was 50% (IQR 36, 55). Of the 53 patients, 28% had an LVEF ≤ 40%, and 2% required inotrope, which was initiated at the same time as SGLT2i. In our study, 89% received empagliflozin and the rest dapagliflozin. The mean duration of treatment with SGLT2i was 19 months (SD ± 9). While on treatment with SGLT2i, 92% of patients were also on guideline-directed medical therapy (GDMT) with at least one agent. The most common GDMT used with SGLT2i was mineralocorticoid receptor antagonist (87%). Following initiation of SGLT2i, acute kidney injury (an increase in serum creatinine ≥ 0.3 mg/dL) developed in 3.8% (2) and urinary tract infection in 6% (3). New orthostatic hypotension was not noted in any patient following the initiation of SGLT2i. SGLT2i was discontinued in 6% (3) patients: following complicated UTI (1), discontinued by the patient (1), and transition to hospice (1). While on treatment with SGLT2i, 11% of the patients were admitted with at least one episode of heart failure exacerbation and no reported mortality for the duration of follow-up. Conclusions Our experience suggests that long-term use of SGLT2i is well-tolerated in patients with ATTR-CA, even with renal dysfunction, and irrespective of LVEF. The side effects were comparable to that reported in other heart failure populations. It also demonstrated that patients did not have worse outcomes while receiving SGLT2i, and hospitalizations for heart failure exacerbation were seen only in a few of the patients. The effects of SGLT2i on morbidity and mortality in ATTR-CA warrant further exploration.

Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis

Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis

Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis

Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience

Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction

Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety

Analysis of a Prospective Registry Study

Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT

Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis

Worsening renal function in acute heart failure in the context of diuretic response

Inhibition Of Sodium-glucose Transport Protein As A Therapeutic Option In The Patients With Transthyretin Cardiac Amyloidosis

Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis

Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease

Left Atrial Dyssynchrony During Sinus Rhythm: A Predictor For Incident Atrial Fibrillation/Flutter In Transthyretin Cardiac Amyloidosis

Right Ventricular Free Wall Strain Predicts ATTR Prognosis as Well as Biomarker- Based Staging Systems

Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy

Prognostic staging system correctly identifies high risk groups in cardiac transthyretin amyloidosis treated with tafamidis

Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury

Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study

Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors

Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis